4//SEC Filing
Bain Capital Life Sciences Investors, LLC 4
Accession 0000950170-24-015358
CIK 0001994702other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 5:26 PM ET
Size
30.8 KB
Accession
0000950170-24-015358
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2024-02-12+2,713,868→ 2,713,868 total(indirect: See footnotes) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 3,163,868 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2024-02-12−12,351,087→ 0 total(indirect: See footnotes)→ Common Stock (2,713,868 underlying)
Transactions
- Conversion
Common Stock
2024-02-12+2,713,868→ 2,713,868 total(indirect: See footnotes) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 3,163,868 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2024-02-12−12,351,087→ 0 total(indirect: See footnotes)→ Common Stock (2,713,868 underlying)
Transactions
- Conversion
Common Stock
2024-02-12+2,713,868→ 2,713,868 total(indirect: See footnotes) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 3,163,868 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2024-02-12−12,351,087→ 0 total(indirect: See footnotes)→ Common Stock (2,713,868 underlying)
Transactions
- Conversion
Common Stock
2024-02-12+2,713,868→ 2,713,868 total(indirect: See footnotes) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 3,163,868 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2024-02-12−12,351,087→ 0 total(indirect: See footnotes)→ Common Stock (2,713,868 underlying)
Transactions
- Conversion
Common Stock
2024-02-12+2,713,868→ 2,713,868 total(indirect: See footnotes) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 3,163,868 total(indirect: See footnotes) - Conversion
Series B Convertible Preferred Stock
2024-02-12−12,351,087→ 0 total(indirect: See footnotes)→ Common Stock (2,713,868 underlying)
Footnotes (4)
- [F1]Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.
- [F2]Represents 12,351,087 shares of the Issuer's Series B Convertible Preferred Stock held directly by Bain Capital Life Sciences Opportunities III, LP ("BCLS Fund III Opportunities").
- [F3]Represents 450,000 shares of the Issuer's Common Stock purchased by BCLS Fund III Opportunities in the Issuer's initial public offering.
- [F4]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC ("BCLS Fund III Opportunities GP"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Documents
Issuer
Kyverna Therapeutics, Inc.
CIK 0001994702
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001703031
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 5:26 PM ET
- Size
- 30.8 KB